ArticleDiabetologia2007
Changing perspectives in diabetes: their impact on its classification.
Article in Diabetologia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 39 citations in OpenAlex.
- Comprehensive evaluation of diabetes subtypes in a European cohort reveals stronger differences of lifestyle, education and psychosocial parameters compared to metabolic or inflammatory factors.Cardiovascular diabetology · 2025Article
- Review
- Is autoimmunity or insulin resistance the primary driver of type 1 diabetes?Current diabetes reports · 2013Review
- Can Roux-en-Y gastric bypass provide a lifelong solution for diabetes mellitus?Canadian journal of surgery. Journal canadien de chirurgie · 2009Article
- T cells cooperate with palmitic acid in induction of beta cell apoptosis.BMC immunology · 2009Article
- Histopathology of type 1 diabetes: old paradigms and new insights.The review of diabetic studies : RDS · 2009Article
- A sub-Saharan African perspective of diabetes.Diabetologia · 2009Review
- Comment on: Gale EAM (2007) To boldly go -- or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571-1575 -- a reply to the editor.Diabetologia · 2007Article
- To boldly go--or to go too boldly? The accelerator hypothesis revisited.Diabetologia · 2007Article
- Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.Molecular medicine (Cambridge, Mass.)Review
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 and type 2 diabetes are usually regarded as distinct disorders, but the convergence of their phenotypes over recent years, the relationship of body weight to the risk of type 1 diabetes, the diminishing importance of the type 1 susceptibility genes and the finding of autoantibodies in patients with type 2 diabetes, invite a different interpretation. The possibility that type 1 and type 2 diabetes, rather than being different, are merely poles of a single spectrum, where variation in the tempo of beta cell loss determines age at onset and symptoms at presentation, has important implications. Correct classification is crucial because it directs appropriate treatment and, where available, prevention. This article argues that type 1 diabetes is currently misclassified, provides evidence that insulin resistance drives type 1 diabetes as it does type 2, and proposes how the 'accelerator hypothesis' can be tested in a randomised controlled trial, which could demonstrate, for the first time, the safe and effective prevention of type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.